Florence Mahuteau-Betzer

Dr. Florence Mahuteau-Betzer


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2007 in Journal of Cell Biology
Verified
Journal Article
Open access
SDsebastien durand
sebastien durand
NCNicolas Cougot
Nicolas Cougot
FMFlorence Mahuteau-Betzer
Florence Mahuteau-Betzer
CNChi-Hung Nguyen
Chi-Hung Nguyen
DGDavid S. Grierson
David S. Grierson
FLFabrice Lejeune
Fabrice Lejeune
In mammals, nonsense-mediated mRNA decay (NMD) is a quality-control mechanism that degrades mRNA harboring a premature termination codon to prevent the synthesis of truncated proteins. To gain insight into the NMD mechanism, we identified NMD inhibitor 1 (NMDI 1) as a small molecule inhibitor of the NMD pathway. We characterized the mode of action of this compound and demonstrated that it acts upstream of hUPF1. NMDI 1 induced the loss of interactions between hSMG5 and hUPF1 and the stabilization of hyperphosphorylated isoforms of hUPF1. Incubation of cells with NMDI 1 allowed us to demonstrate that NMD factors and mRNAs subject to NMD transit through processing bodies (P-bodies), as is the case in yeast. The results suggest a model in which mRNA and NMD factors are sequentially recruited to P-bodies.

21 April 2005 in Organic Letters
Verified
Journal Article
Closed access
GCGérard Cahiez
Gérard Cahiez
CCChristophe Chaboche
Christophe Chaboche
FMFlorence Mahuteau-Betzer
Florence Mahuteau-Betzer
MAMathieu Ahr
Mathieu Ahr

23 August 2008 in Organic Letters
Verified
Journal Article
Closed access
FBFrançois Besselièvre
François Besselièvre
SPSandrine Piguel
Sandrine Piguel
FMFlorence Mahuteau-Betzer
Florence Mahuteau-Betzer
DGDavid S. Grierson
David S. Grierson

19 March 2008 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
FBFrançois Besselièvre
François Besselièvre
FMFlorence Mahuteau-Betzer
Florence Mahuteau-Betzer
DGDavid S. Grierson
David S. Grierson
SPSandrine Piguel
Sandrine Piguel

5 August 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
BDBlaise Dumat
Blaise Dumat
GBGuillaume Bordeau
Guillaume Bordeau
EFElodie Faurel-Paul
Elodie Faurel-Paul
FMFlorence Mahuteau-Betzer
Florence Mahuteau-Betzer
NSNicolas Saettel
Nicolas Saettel
MTMarie-Paule Teulade-Fichou
Marie-Paule Teulade-Fichou

9 April 2015 in Retrovirology
Verified
Journal Article
Open access
PDF file
NCNoëlie Campos
Noëlie Campos
RMRenier Myburgh
Renier Myburgh
AGAude Garcel
Aude Garcel
AVAudrey Vautrin
Audrey Vautrin
LLLaure Lapasset
Laure Lapasset
JTJamal Tazi
Jamal Tazi
Current therapies have succeeded in controlling AIDS pandemic. However, there is a continuing need for new drugs, in particular those acting through new and as yet unexplored mechanisms of action to achieve HIV infection cure. We took advantage of the unique feature of proviral genome to require both activation and inhibition of splicing of viral transcripts to develop molecules capable of achieving long lasting effect on viral replication in humanized mouse models through inhibition of Rev-mediated viral RNA biogenesis. Current HIV therapies reduce viral load during treatment but titers rebound after treatment is discontinued. We devised a new drug that has a long lasting effect after viral load reduction. We demonstrate here that ABX464 compromises HIV replication of clinical isolates of different subtypes without selecting for drug resistance in PBMCs or macrophages. ABX464 alone, also efficiently compromised viral proliferation in two humanized mouse models infected with HIV that require a combination of 3TC, Raltegravir and Tenofovir (HAART) to achieve viral inhibition in current protocols. Crucially, while viral load increased dramatically just one week after stopping HAART treatment, only slight rebound was observed following treatment cessation with ABX464 and the magnitude of the rebound was maintained below to that of HAART for two months after stopping the treatment. Using a system to visualize single HIV RNA molecules in living cells, we show that ABX464 inhibits viral replication by preventing Rev-mediated export of unspliced HIV-1 transcripts to the cytoplasm and by interacting with the Cap Binding Complex (CBC). Deep sequencing of viral RNA from treated cells established that retained viral RNA is massively spliced but importantly, normal cellular splicing is unaffected by the drug. Consistently ABX464 is non-toxic in humans and therefore represents a promising complement to current HIV therapies. ABX464 represents a novel class of anti-HIV molecules with unique properties. ABX464 has a long lasting effect in humanized mice and neutralizes the expression of HIV-1 proviral genome of infected immune cells including reservoirs and it is therefore a promising drug toward a functional cure of HIV.